[Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies].

Autor:	Roppelt AA; City Clinical Hospital №52.; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology., Lebedkina MS; City Clinical Hospital №52., Chernov AA; City Clinical Hospital №52.; Russian Medical Academy of Continuous Professional Education., Kruglova TS; City Clinical Hospital №52., Mukhina OA; City Clinical Hospital №52., Yukhnovskaya YD; Sechenov First Moscow State Medical University (Sechenov University)., Samedova FA; Sechenov First Moscow State Medical University (Sechenov University)., Mаrkina UA; City Clinical Hospital №52., Andrenova GV; City Clinical Hospital №52., Karaulov AV; Sechenov First Moscow State Medical University (Sechenov University)., Lysenko MA; City Clinical Hospital №52.; Pirogov Russian National Research Medical University., Fomina DS; City Clinical Hospital №52.; Sechenov First Moscow State Medical University (Sechenov University).
Jazyk:	ruština
Zdroj:	Terapevticheskii arkhiv [Ter Arkh] 2023 Feb 24; Vol. 95 (1), pp. 78-84. Date of Electronic Publication: 2023 Feb 24.
DOI:	10.26442/00403660.2023.01.202088
Abstrakt:	Background: Primary immunodeficiencies (PIDs), now known as inborn errors of immunity, are a group of inherited diseases caused by defects in the genes that control the immune response. Patients with PIDs have risks of developing a severe course and/or death in COVID-19. Passive immunization with long-acting monoclonal antibodies (MABs) to SARS-CoV-2 should be considered as pre-exposure prophylaxis in patients with PIDs. Tixagevimab/cilgavimab is a combination of MABs that bind to the SARS-CoV-2 spike protein. Aim: To evaluate the efficacy and safety of pre-exposure prophylaxis of new SARS-CoV-2 infection in PIDs with the combination of tixagevimab/cilgavimab. Materials and Methods: Forty eight patients diagnosed with PIDs were included in the study. Median follow-up after drug administration was 174 days. The total number of confirmed coronavirus infections in patients with PIDs as well as 6 months before and after administration of MAT were assessed. Results: In the analyzed cohort, the overall incidence of COVID-19 from pandemic onset to MABs administration was 75% (36/48), with 31% (11/36) of over-infected patients having had the infection more than once. The incidence of COVID-19 immediately 6 months before the introduction of tixagevimab/cilgavimab was 40%. All patients who had COVID-19 after pre-exposure prophylaxis had a mild infection. The incidence of COVID-19 6 months after tixagevimab/cilgavimab administration significantly decreased compared to the incidence 6 months before administration (7 and 40%, respectively; p <0.001). Conclusion: The use of tixagevimab/cilgavimab in patients with PIDs is effective as pre-exposure prophylaxis and reduces the risk of severe COVID-19.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu